FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367163944> ?p ?o ?g. }

• W4367163944 endingPage "807" @default.
• W4367163944 startingPage "797" @default.
• W4367163944 abstract "Due to less sensitivity to classic tyrosine kinase inhibitors, effective first-line treatment is limited in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) exon 20 insertion (ex20ins) mutations. Meanwhile, the impact of driver genes on the efficacy of PD-1 inhibitors is discrepant. Our study aimed to assess the clinical response to immunotherapy in NSCLC patients with EGFR or HER2 ex20ins mutations. In parallel, patients treated with chemotherapy but without immunotherapy were included as controls.We retrospectively reviewed patients harboring ex20ins mutations treated with immune checkpoint inhibitors (ICIs) and/or chemotherapy in the real world. The clinical response was assessed by progression-free survival (PFS) and the objective response rate (ORR). Propensity score matching (PSM) was performed to control for confounding factors between immunotherapy and chemotherapy.Of 72 patients enrolled, 38 had been treated with one line of single-agent immunotherapy or combined therapy including immunotherapy, and 34 had received conventional chemotherapy without immunotherapy. Among patients treated with immunotherapy, the median PFS was 10.7 months [95% confidence interval (CI): 8.2-13.2 months] in the first-line setting, with an ORR of 50% (8/16). The median PFS was significantly longer in the first-line immunotherapy group than in the chemotherapy group (10.7 vs. 4.6 months, P<0.001). A trend of an increased ORR in patients who received ICIs was observed compared with chemotherapy, but there was no statistical difference (50% vs. 21.9%, P=0.096). After PSM, the median PFS with first-line immunotherapy was still longer than that with chemotherapy (10.7 vs. 4.6 months, P=0.028). Grade 3-4 adverse events (AEs) were observed in 13.2% (5/38) of patients, with the majority developing granulocytopenia (40%, 2/5). One patient discontinued treatment due to a grade 3 rash after three cycles of ICI plus anlotinib treatment.The results showed that immunotherapy combined with chemotherapy may play a role in the first-line treatment of NSCLC patients with ex20ins mutations. This finding requires further investigation for application." @default.
• W4367163944 created "2023-04-28" @default.
• W4367163944 creator A5010431622 @default.
• W4367163944 creator A5013152328 @default.
• W4367163944 creator A5015723603 @default.
• W4367163944 creator A5049829974 @default.
• W4367163944 creator A5066954778 @default.
• W4367163944 creator A5076344513 @default.
• W4367163944 creator A5086664284 @default.
• W4367163944 date "2023-04-01" @default.
• W4367163944 modified "2023-09-27" @default.
• W4367163944 title "Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis" @default.
• W4367163944 cites W2075445339 @default.
• W4367163944 cites W2112854176 @default.
• W4367163944 cites W2139804581 @default.
• W4367163944 cites W2151016309 @default.
• W4367163944 cites W2152481222 @default.
• W4367163944 cites W2175694606 @default.
• W4367163944 cites W2198093519 @default.
• W4367163944 cites W2461029491 @default.
• W4367163944 cites W2560367415 @default.
• W4367163944 cites W2572174216 @default.
• W4367163944 cites W2610994169 @default.
• W4367163944 cites W2770312776 @default.
• W4367163944 cites W2777461561 @default.
• W4367163944 cites W2796582438 @default.
• W4367163944 cites W2799334305 @default.
• W4367163944 cites W2801651204 @default.
• W4367163944 cites W2805354595 @default.
• W4367163944 cites W2897449632 @default.
• W4367163944 cites W2916877067 @default.
• W4367163944 cites W2922107046 @default.
• W4367163944 cites W2946166987 @default.
• W4367163944 cites W2946386783 @default.
• W4367163944 cites W3012479383 @default.
• W4367163944 cites W3013632168 @default.
• W4367163944 cites W3034192486 @default.
• W4367163944 cites W3037442044 @default.
• W4367163944 cites W3155198217 @default.
• W4367163944 cites W3191219220 @default.
• W4367163944 cites W3206796634 @default.
• W4367163944 cites W4309764573 @default.
• W4367163944 doi "https://doi.org/10.21037/tlcr-23-167" @default.
• W4367163944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37197626" @default.
• W4367163944 hasPublicationYear "2023" @default.
• W4367163944 type Work @default.
• W4367163944 citedByCount "2" @default.
• W4367163944 countsByYear W43671639442023 @default.
• W4367163944 crossrefType "journal-article" @default.
• W4367163944 hasAuthorship W4367163944A5010431622 @default.
• W4367163944 hasAuthorship W4367163944A5013152328 @default.
• W4367163944 hasAuthorship W4367163944A5015723603 @default.
• W4367163944 hasAuthorship W4367163944A5049829974 @default.
• W4367163944 hasAuthorship W4367163944A5066954778 @default.
• W4367163944 hasAuthorship W4367163944A5076344513 @default.
• W4367163944 hasAuthorship W4367163944A5086664284 @default.
• W4367163944 hasBestOaLocation W43671639441 @default.
• W4367163944 hasConcept C121608353 @default.
• W4367163944 hasConcept C126322002 @default.
• W4367163944 hasConcept C143998085 @default.
• W4367163944 hasConcept C2776256026 @default.
• W4367163944 hasConcept C2776694085 @default.
• W4367163944 hasConcept C2777701055 @default.
• W4367163944 hasConcept C2779438470 @default.
• W4367163944 hasConcept C71924100 @default.
• W4367163944 hasConceptScore W4367163944C121608353 @default.
• W4367163944 hasConceptScore W4367163944C126322002 @default.
• W4367163944 hasConceptScore W4367163944C143998085 @default.
• W4367163944 hasConceptScore W4367163944C2776256026 @default.
• W4367163944 hasConceptScore W4367163944C2776694085 @default.
• W4367163944 hasConceptScore W4367163944C2777701055 @default.
• W4367163944 hasConceptScore W4367163944C2779438470 @default.
• W4367163944 hasConceptScore W4367163944C71924100 @default.
• W4367163944 hasIssue "4" @default.
• W4367163944 hasLocation W43671639441 @default.
• W4367163944 hasLocation W43671639442 @default.
• W4367163944 hasLocation W43671639443 @default.
• W4367163944 hasOpenAccess W4367163944 @default.
• W4367163944 hasPrimaryLocation W43671639441 @default.
• W4367163944 hasRelatedWork W2054822224 @default.
• W4367163944 hasRelatedWork W2055244776 @default.
• W4367163944 hasRelatedWork W2186047679 @default.
• W4367163944 hasRelatedWork W2348529436 @default.
• W4367163944 hasRelatedWork W2390152934 @default.
• W4367163944 hasRelatedWork W2413020017 @default.
• W4367163944 hasRelatedWork W247981852 @default.
• W4367163944 hasRelatedWork W2542192317 @default.
• W4367163944 hasRelatedWork W2948610106 @default.
• W4367163944 hasRelatedWork W2597201175 @default.
• W4367163944 hasVolume "12" @default.
• W4367163944 isParatext "false" @default.
• W4367163944 isRetracted "false" @default.
• W4367163944 workType "article" @default.